Management of suspected temporal arteritis. A decision analysis

Temporal arteritis is a condition that can lead to significant complications if not properly diagnosed. Prior research has shown that diagnostic approaches vary widely, with some clinicians opting for bilateral biopsies while others use corticosteroid therapy. However, the economic implications of these choices remain unclear. No prior work had resolved the cost-effectiveness of different strategies across varying disease prevalence. That uncertainty drove the need for a structured decision analysis. Existing models do not incorporate the full range of clinical and economic variables. This gap motivated the development of a decision model to evaluate management strategies. The model aims to provide guidance on when to biopsy or initiate treatment. It also considers the risk of blindness as a key outcome. The study addresses the need for evidence-based clinical decision-making.

The study aimed to evaluate the cost-effectiveness of various diagnostic and treatment strategies for suspected temporal arteritis. It sought to determine the optimal approach based on disease prevalence and clinical suspicion. The researchers focused on the trade-offs between diagnostic accuracy and economic impact. They considered the risk of blindness as a critical factor in decision-making. The study's motivation was to provide clinicians with a framework for choosing between biopsies and corticosteroids. It also aimed to quantify the economic consequences of diagnostic delays. The researchers wanted to identify thresholds for action based on disease probability. The analysis was designed to inform clinical guidelines and patient care decisions.

The researchers constructed a decision model to simulate the outcomes of different management strategies. They used a sensitivity analysis to assess the impact of varying disease prevalence. The model incorporated probabilities of blindness and treatment costs. It compared unilateral and bilateral biopsies as diagnostic options. The analysis also evaluated the cost-effectiveness of empiric corticosteroid therapy. The model was structured to reflect real-world clinical scenarios. It included variables such as biopsy failure rates and treatment success rates. The researchers used a cost-minimization approach to determine optimal strategies.

The analysis found that empiric steroids are the cheapest option when disease suspicion is high (greater than 30%). At low suspicion (less than 1.4%), the model suggested that not biopsying is cost-effective. Bilateral biopsy was identified as the most cost-effective initial diagnostic procedure. If a unilateral biopsy is negative, a second biopsy is always cost-effective. The model showed that the risk of blindness significantly influences management decisions. The cost of blindness was estimated at $100,000 per case. The analysis included a range of disease prevalence from 1% to 50%. The results were consistent across different prevalence scenarios.

The authors concluded that the risk of blindness must be considered when deciding not to biopsy. They proposed that at low suspicion (less than 1.4%), forgoing biopsy is cost-effective. At high suspicion (greater than 30%), empiric steroids are the most cost-effective approach. Bilateral biopsy is recommended as the initial diagnostic procedure. A second biopsy is always cost-effective if the first is negative. The model suggests that diagnostic accuracy is crucial in preventing blindness. The findings support a threshold-based approach to management. The authors emphasized the importance of balancing diagnostic accuracy with economic considerations.